Acadia calls early halt to Nuplazid psychosis trial after promising interim results

10th September 2019 Uncategorised 0

Acadia was stung hard after its schizophrenia hopes for flagship Nuplazid fell flat back in late July. On the heels of that failure, Acadia is calling off a trial in dementia-related psychosis after it saw promising interim results for the drug.

More: Acadia calls early halt to Nuplazid psychosis trial after promising interim results
Source: fierce